The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) closed at $4.19 down -4.99% from its previous closing price of $4.41. In other words, the price has decreased by -$4.99 from its previous closing price. On the day, 1.03 million shares were traded.
Ratios:
For a deeper understanding of Corvus Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.92 and its Current Ratio is at 0.92. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 02, 2025, initiated with a Buy rating and assigned the stock a target price of $11.
On August 18, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 06 ’24 when Jones William Benton bought 20,000 shares for $1.73 per share. The transaction valued at 34,624 led to the insider holds 153,773 shares of the business.
MILLER RICHARD A MD bought 577,634 shares of CRVS for $1,000,000 on May 06 ’24. The President and CEO now owns 577,634 shares after completing the transaction at $1.73 per share.
Stock Price History:
Over the past 52 weeks, CRVS has reached a high of $10.00, while it has fallen to a 52-week low of $1.30. The 50-Day Moving Average of the stock is -23.72%, while the 200-Day Moving Average is calculated to be -12.75%.
Shares Statistics:
A total of 62.58M shares are outstanding, with a floating share count of 47.01M. Insiders hold about 26.84% of the company’s shares, while institutions hold 36.15% stake in the company.
